Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kappelle, A.C.
Right arrow Articles by Heimans, J.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kappelle, A.C.
Right arrow Articles by Heimans, J.J.
Related Collections
Right arrow All Oncology
Right arrow Primary brain tumor
Right arrow Chemotherapy-tumor
Neurology 2001;56:118-120
© 2001 American Academy of Neurology
Brief Communications

PCV chemotherapy for recurrent glioblastoma multiforme

A.C. Kappelle, MD;, T.J. Postma, MD;, M.J.B. Taphoorn, MD;, G.J. Groeneveld, MD;, M.J. van den Bent, MD;, C.J. van Groeningen, MD;, B.A. Zonnenberg, MD;, K.C.A. Sneeuw, MSc and J.J. Heimans, MD

From the Departments of Neurology and Medical Oncology (Drs. Kappelle, Postma, van Groeningen, and Heimans), University Hospital Vrije Universiteit, Amsterdam; Departments of Neurology and Medical Oncology (Drs. Taphoorn, Groeneveld, and Zonnenberg) University Medical Center, Utrecht; Department of Neuro-oncology (Dr. van den Bent) University Hospital Rotterdam/Daniel Den Hoed Cancer Center, Rotterdam; and Comprehensive Cancer Center (K.C.A. Sneeuw), Amsterdam, the Netherlands.

Address correspondence and reprint requests to Dr. T.J. Postma, Department of Neurology, University Hospital Vrije Universiteit, PO Box 7057, 1007 MB Amsterdam, the Netherlands; e-mail: TJ.Postma{at}azvu.nl

The authors evaluated response, time to progression (TTP), survival, prognostic factors, and toxicity in 63 patients with a recurrent glioblastoma multiforme treated with procarbazine, lomustine, and vincristine (PCV) chemotherapy. Complete and partial response was observed in two (3%) and five patients (8%). In 16 patients (25%), stable disease was observed. Median TTP and survival were 13 and 33 weeks. Age < 40 years and Karnofsky Performance Status >= 90 were associated with longer TTP and survival. PCV treatment was generally well tolerated.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
D. Sarkar, E. S. Park, L. Emdad, S.-G. Lee, Z.-z. Su, and P. B. Fisher
Molecular Basis of Nuclear Factor-{kappa}B Activation by Astrocyte Elevated Gene-1
Cancer Res., March 1, 2008; 68(5): 1478 - 1484.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
F. Schmidt, J. Fischer, U. Herrlinger, K. Dietz, J. Dichgans, and M. Weller
PCV chemotherapy for recurrent glioblastoma
Neurology, February 28, 2006; 66(4): 587 - 589.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Stupp, M. E. Hegi, M. J. van den Bent, W. P. Mason, M. Weller, R. O. Mirimanoff, J. G. Cairncross, and on behalf of the European Organisation for Researc
Changing paradigms--an update on the multidisciplinary management of malignant glioma.
Oncologist, February 1, 2006; 11(2): 165 - 180.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Eramo, R. Pallini, F. Lotti, G. Sette, M. Patti, M. Bartucci, L. Ricci-Vitiani, M. Signore, G. Stassi, L. M. Larocca, et al.
Inhibition of DNA Methylation Sensitizes Glioblastoma for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Destruction
Cancer Res., December 15, 2005; 65(24): 11469 - 11477.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Brandes, A. Tosoni, U. Basso, M. Reni, F. Valduga, S. Monfardini, P. Amista, L. Nicolardi, G. Sotti, and M. Ermani
Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
J. Clin. Oncol., December 1, 2004; 22(23): 4779 - 4786.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
S. L. Chua, M. A. Rosenthal, S. S. Wong, D. M. Ashley, A.-m. Woods, A. Dowling, and L. M. Cher
Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme
Neuro-oncol, January 1, 2004; 6(1): 38 - 43.
[Abstract] [PDF]

Home page
 JCOHome page
M. J. Vos, O. S. Hoekstra, F. Barkhof, J. Berkhof, J. J. Heimans, C. J. van Groeningen, W. P. Vandertop, B. J. Slotman, and T. J. Postma
Thallium-201 Single-Photon Emission Computed Tomography As an Early Predictor of Outcome in Recurrent Glioma
J. Clin. Oncol., October 1, 2003; 21(19): 3559 - 3565.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Bello, C. Giussani, G. Carrabba, M. Pluderi, V. Lucini, M. Pannacci, D. Caronzolo, G. Tomei, R. Villani, F. Scaglione, et al.
Suppression of Malignant Glioma Recurrence in a Newly Developed Animal Model by Endogenous Inhibitors
Clin. Cancer Res., November 1, 2002; 8(11): 3539 - 3548.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. A. Brandes, S. Turazzi, U. Basso, L. M. Pasetto, B. Guglielmi, L. Volpin, P. Iuzzolino, P. Amista, G. Pinna, R. Scienza, et al.
A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme
Neurology, June 25, 2002; 58(12): 1759 - 1764.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. Boiardi, T. J. Postma, M. J. B. Taphoorn, M. J. van den Bent, A. C. Kappelle, and J. J. Heimans
PCV chemotherapy for recurrent glioblastoma multiforme
Neurology, June 26, 2001; 56(12): 1782 - 1782.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by AAN Enterprises, Inc.